- Home
- SILO vs AIMD Comparison
SILO vs AIMD Comparison
Compare SILO & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILO | AIMD |
|---|---|---|
| Founded | 2010 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 10.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SILO | AIMD |
|---|---|---|
| Price | $0.37 | $2.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.8K | 28.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $72,102.00 | ★ $113,037.00 |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $0.36 | $1.78 |
| 52 Week High | $3.37 | $5.00 |
Technical Indicators
Market Signals| Indicator | SILO | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 30.47 | 41.63 |
| Support Level | $0.42 | $1.94 |
| Resistance Level | $0.46 | $2.29 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 2.73 | 27.72 |
Price Performance
Historical ComparisonAbout SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.